Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. more
Time Frame | RGLS | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.63% | -2.12% | -3% |
1-Month Return | 13.57% | -3.42% | -0.73% |
3-Month Return | -12.64% | -11.13% | 2.87% |
6-Month Return | -36.9% | -5.74% | 7.17% |
1-Year Return | 20.45% | 3.97% | 25.31% |
3-Year Return | -52.71% | 1.05% | 28.38% |
5-Year Return | -75.16% | 34.37% | 81.89% |
10-Year Return | -99.92% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 6.83M | 10.01M | 10.02K | - | - | [{"date":"2019-12-31","value":68.28,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.1,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 12.35M | 15.35K | 459.00K | 122.00K | 21.15M | [{"date":"2019-12-31","value":58.38,"profit":true},{"date":"2020-12-31","value":0.07,"profit":true},{"date":"2021-12-31","value":2.17,"profit":true},{"date":"2022-12-31","value":0.58,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 6.83M | 10.01M | (459.00K) | (122.00K) | (21.15M) | [{"date":"2019-12-31","value":68.28,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-4.59,"profit":false},{"date":"2022-12-31","value":-1.22,"profit":false},{"date":"2023-12-31","value":-211.39,"profit":false}] |
Gross Margin | 100.00% | 100.00% | (4579.92%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-4579.92,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 23.67M | 24.16M | 27.82M | 28.24M | 9.96M | [{"date":"2019-12-31","value":83.81,"profit":true},{"date":"2020-12-31","value":85.56,"profit":true},{"date":"2021-12-31","value":98.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":35.26,"profit":true}] |
Operating Income | (16.83M) | (14.15M) | (27.82M) | (28.24M) | (31.11M) | [{"date":"2019-12-31","value":-1683400000,"profit":false},{"date":"2020-12-31","value":-1415500000,"profit":false},{"date":"2021-12-31","value":-2781600000,"profit":false},{"date":"2022-12-31","value":-2823900000,"profit":false},{"date":"2023-12-31","value":-3110900000,"profit":false}] |
Total Non-Operating Income/Expense | (3.51M) | (3.15M) | 18.00K | (166.00K) | 2.04M | [{"date":"2019-12-31","value":-171.92,"profit":false},{"date":"2020-12-31","value":-154.11,"profit":false},{"date":"2021-12-31","value":0.88,"profit":true},{"date":"2022-12-31","value":-8.12,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (18.59M) | (15.73M) | (27.81M) | (28.32M) | (30.04M) | [{"date":"2019-12-31","value":-1859100000,"profit":false},{"date":"2020-12-31","value":-1573000000,"profit":false},{"date":"2021-12-31","value":-2780700000,"profit":false},{"date":"2022-12-31","value":-2832200000,"profit":false},{"date":"2023-12-31","value":-3003600000,"profit":false}] |
Income Taxes | 1.00K | (467.00K) | 1.00K | 1.00K | 1.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-46700,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (18.59M) | (15.26M) | (27.81M) | (28.32M) | (30.04M) | [{"date":"2019-12-31","value":-1859200000,"profit":false},{"date":"2020-12-31","value":-1526300000,"profit":false},{"date":"2021-12-31","value":-2780800000,"profit":false},{"date":"2022-12-31","value":-2832300000,"profit":false},{"date":"2023-12-31","value":-3003700000,"profit":false}] |
Income From Continuous Operations | (18.59M) | (15.73M) | (27.81M) | (28.32M) | (28.77M) | [{"date":"2019-12-31","value":-1859200000,"profit":false},{"date":"2020-12-31","value":-1573000000,"profit":false},{"date":"2021-12-31","value":-2780800000,"profit":false},{"date":"2022-12-31","value":-2832300000,"profit":false},{"date":"2023-12-31","value":-2877100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (18.59M) | (15.26M) | (27.81M) | (28.32M) | (30.04M) | [{"date":"2019-12-31","value":-1859200000,"profit":false},{"date":"2020-12-31","value":-1526300000,"profit":false},{"date":"2021-12-31","value":-2780800000,"profit":false},{"date":"2022-12-31","value":-2832300000,"profit":false},{"date":"2023-12-31","value":-3003700000,"profit":false}] |
EPS (Diluted) | (11.00) | (5.50) | (3.30) | (1.90) | (1.59) | [{"date":"2019-12-31","value":-1100,"profit":false},{"date":"2020-12-31","value":-550,"profit":false},{"date":"2021-12-31","value":-330,"profit":false},{"date":"2022-12-31","value":-190,"profit":false},{"date":"2023-12-31","value":-159,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RGLS | |
---|---|
Cash Ratio | 13.47 |
Current Ratio | 14.14 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RGLS | |
---|---|
ROA (LTM) | -42.39% |
ROE (LTM) | -72.36% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RGLS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.07 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.93 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RGLS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 7.43 |
P/B | 1.20 |
Price/FCF | NM |
EV/R | 0.66 |
EV/Ebitda | 0.57 |
PEG | NM |
Regulus Therapeutics Inc (RGLS) share price today is $1.59
Yes, Indians can buy shares of Regulus Therapeutics Inc (RGLS) on Vested. To buy Regulus Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RGLS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Regulus Therapeutics Inc (RGLS) via the Vested app. You can start investing in Regulus Therapeutics Inc (RGLS) with a minimum investment of $1.
You can invest in shares of Regulus Therapeutics Inc (RGLS) via Vested in three simple steps:
The 52-week high price of Regulus Therapeutics Inc (RGLS) is $3. The 52-week low price of Regulus Therapeutics Inc (RGLS) is $1.08.
The price-to-earnings (P/E) ratio of Regulus Therapeutics Inc (RGLS) is
The price-to-book (P/B) ratio of Regulus Therapeutics Inc (RGLS) is 1.20
The dividend yield of Regulus Therapeutics Inc (RGLS) is 0.00%
The market capitalization of Regulus Therapeutics Inc (RGLS) is $101.53M
The stock symbol (or ticker) of Regulus Therapeutics Inc is RGLS